Drugs / Tobramycin
Tobramycin
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Tobi Podhaler | — | 2011-07-20 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | NEBCIN | — | 1975-09-03 – 1997-10-01 | fda.gov ↗ |
| Approved | US (FDA) | NEBCIN | — | 1975-06-11 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 1975
EU approved 2011
1
1
1
1
1
1
1
5
3
5
4
1
2
4
4
5
2
4
4
4
2
5
3
4
2
2
19741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05849090 | Mar 2023 → Dec 2024 | infectious disease | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT05076955 | Mar 2021 → Aug 2022 | ulcer of lower limbs | University of Mississippi Medical Center | Unknown | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT04560179 | Mar 2022 → Dec 2023 | bronchopulmonary dysplasia | Erik Allen Jensen | Completed | No outcome recorded |
| Phase 1 | NCT05353101 | Jul 2020 → Jun 2021 | vernal keratoconjunctivitis | Second Affiliated Hospital of Nanchang University | Completed | No outcome recorded |
| Phase 1 | NCT03904836 | Jan → Dec 2019 | end stage renal failure | Maisonneuve-Rosemont Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02212587 | Sep 2014 → May 2016 | burkholderia infectious disease, cystic fibrosis | Unity Health Toronto | Completed | No outcome recorded |
| Phase 1 | NCT02207426 | Jul → Aug 2014 | — | Pharmaero ApS | Completed | No outcome recorded |
| Phase 1 | NCT00399945 | May 2006 → ? | cystic fibrosis | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00420836 | Apr 2006 → ? | cystic fibrosis | Novartis | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06016088 | Apr 2024 → Apr 2026 | Pseudomonas aeruginosa infectious disease, cystic fibrosis, respiratory tract infectious disorder | Respirion Pharmaceuticals Pty Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT03485456 | May 2019 → Nov 2020 | cystic fibrosis | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1/2 | NCT03673956 | Sep 2018 → Feb 2021 | chronic rhinosinusitis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT02334384 | Apr 2016 → Aug 2017 | furunculosis | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 1/2 | NCT02269969 | Mar → Dec 2015 | bacterial infectious disease | Sandra Walker | Completed | No outcome recorded |
| Phase 1/2 | NCT02035488 | Oct 2013 → Dec 2014 | bronchiectasis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 212 trials · 1 met primary | ||||||
| Phase 2 | NCT07463339 | May 2026 → Apr 2027 expected | — | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05607030 | Jan 2023 → May 2024 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05169229 | Apr 2022 → Dec 2028 expected | osteoarthritis, hip, periprosthetic joint infection | University Hospital, Linkoeping | Recruiting | No outcome recorded |
| Phase 2 | NCT04662632 | Nov 2021 → Mar 2023 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03935828 | Jun 2019 → Dec 2020 | chronic rhinosinusitis, poisoning | United States Naval Medical Center, San Diego | Withdrawn | No outcome recorded |
| Phase 2 | NCT03721328 | Oct 2018 → Aug 2020 | periprosthetic joint infection | Osteal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02712983 | Feb 2017 → Mar 2019 | bronchiectasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01570192 | Sep 2010 → Apr 2015 | bacterial pneumonia | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00794586 | Nov 2008 → Feb 2010 | cystic fibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00699803 | May → Aug 2008 | cataract | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00447837 | Oct 2006 → Dec 2007 | chronic rhinosinusitis | Naryx Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00006280 | Feb 2000 → Feb 2002 | cystic fibrosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 326 trials · 4 met primary · 2 missed | ||||||
| Phase 3 | NCT05865743 | Oct 2024 → Dec 2027 expected | carcinoma of esophagus | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05615844 | Nov 2023 → Mar 2027 expected | — | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 3 | NCT04964947 | Jan 2022 → Jul 2026 | skin infection | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04597008 | May 2021 → Jul 2025 | — | Major Extremity Trauma Research Consortium | Completed | No outcome recorded |
| Phase 3 | NCT04678154 | May 2021 → Sep 2026 overdue | — | Major Extremity Trauma Research Consortium | Recruiting | No outcome recorded |
| Phase 3 | NCT03715322 | Oct 2018 → Apr 2021 | Pseudomonas infection, bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | Met primary |
| Phase 3 | NCT03066453 | Jun 2017 → Jan 2020 | cystic fibrosis | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 3 | NCT02389036 | May 2017 → Apr 2023 | critical illness polyneuropathy, infectious disease with sepsis | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT02888730 | Feb → May 2017 | chronic rhinosinusitis, cystic fibrosis, lung disorder | Virginie ESCABASSE | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03705962 | Jul 2015 → Mar 2019 | — | University of Virginia | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03341741 | Mar 2014 → Dec 2015 | cystic fibrosis | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 3 | NCT02208154 | Dec 2013 → Oct 2017 | bacterial infectious disease with sepsis | MJM Bonten | Completed | Missed primary |
| Phase 3 | NCT01227915 | Feb 2011 | bacterial conjunctivitis | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT01082367 | Apr 2010 → Jun 2015 | Pseudomonas aeruginosa infectious disease | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01102244 | Apr → Jun 2010 | blepharitis | Alcon Research | Completed | Met primary |
| Phase 3 | NCT01069705 | Feb 2010 → Mar 2012 | Pseudomonas aeruginosa infectious disease, respiratory tract infectious disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01111383 | Sep 2009 → May 2011 | cystic fibrosis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00982930 | Aug 2009 → Oct 2011 | Pseudomonas aeruginosa infectious disease, cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00918957 | Jun 2009 → May 2011 | cystic fibrosis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT00885365 | Apr 2009 → Apr 2010 | cystic fibrosis | Chiesi Farmaceutici S.p.A. | Completed | Met primary |
| Phase 3 | NCT00854061 | Feb → Aug 2009 | cataract | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT00634192 | Feb 2008 → Feb 2009 | Pseudomonas infection | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00388505 | Feb 2006 → Mar 2009 | cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00125346 | Sep 2005 → Feb 2007 | cystic fibrosis | Novartis | Terminated | No outcome recorded |
| Phase 3 | NCT00391976 | Nov 2003 → Jan 2008 | cystic fibrosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00004829 | Jun 1995 → May 1998 | bacterial infectious disease, cystic fibrosis | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 416 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07856355 | Oct 2026 → Oct 2028 expected | — | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04872400 | Jun 2021 → Sep 2023 | disease of bone structure, skin infection | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT04297631 | Feb → Aug 2020 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03928522 | Jan → Sep 2019 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03308253 | Jul 2018 → Jun 2019 | — | McMaster University | Unknown | No outcome recorded |
| Phase 4 | NCT02478710 | Jun 2015 → Feb 2017 | — | Wright State University | Terminated | No outcome recorded |
| Phase 4 | NCT02440828 | Mar 2015 → Mar 2020 | — | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02248922 | Jan 2015 → Apr 2017 | pneumonia caused by pseudomonas aeruginosa infection | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02015663 | Jan → Dec 2014 | cystic fibrosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01775137 | Feb 2013 → Nov 2014 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01740947 | Jan 2013 → Mar 2017 | colorectal cancer | H. Jaap Bonjer, PhD | Terminated | Missed primary |
| Phase 4 | NCT01519661 | Jan 2012 → Jan 2014 | Pseudomonas aeruginosa infectious disease, respiratory tract infectious disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01608555 | Jan → Jul 2012 | cystic fibrosis | University of Milan | Completed | No outcome recorded |
| Phase 4 | NCT00420628 | Nov 2006 → Jan 2009 | chalazion | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 4 | NCT00257790 | Sep 2001 → Mar 2005 | cancer, neutropenia | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01559753 | Jan 1998 → Sep 2002 | — | Centre Hospitalier Universitaire de Besancon | Completed | Met primary |
| Phase not applicable3 trials | ||||||
| — | NCT07332936 | Jul 2023 → Jun 2024 | acute apical periodontitis, pulpitis | Umm Al-Qura University | Completed | No outcome recorded |
| — | NCT02958514 | Nov 2016 → Feb 2017 | dry eye syndrome | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT00153634 | Mar 2004 → Nov 2007 | chronic bronchitis, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06383611 | — | periprosthetic joint infection | Osteal Therapeutics, Inc. | Temporarily not available | No outcome recorded |
| Comparator or background therapy48 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06175676 Comparator | Dec 2021 → Jun 2023 | chronic dacryocystitis | Tianjin Medical University Eye Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00695435 Comparator | Jun 2008 | dry eye syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 1 | NCT00823238 Comparator | Jul 2004 → May 2008 | cystic fibrosis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT07308938 Background | Oct 2026 → Dec 2029 expected | corneal ulcer | Vishal Jhanji | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00774072 Comparator | Oct 2008 → Nov 2010 | Pseudomonas aeruginosa infectious disease, cystic fibrosis | University of Jena | Completed | No outcome recorded |
| Phase 2 | NCT00097773 Comparator | Sep 2004 → Jun 2009 | chronic obstructive pulmonary disease, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT07812129 Comparator | Nov 2023 → May 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT02657473 Comparator | Aug 2016 → Dec 2019 | bronchiectasis | Medical Center Alkmaar | Completed | No outcome recorded |
| Phase 3 | NCT05429671 Comparator | Jun 2022 → Nov 2023 | — | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| Phase 3 | NCT03739528 Comparator | Sep → Dec 2018 | cataract | NTC srl | Completed | No outcome recorded |
| Phase 3 | NCT02717871 Comparator | Mar 2016 → Oct 2020 | keratitis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 3 | NCT02054156 Comparator | Jun 2014 → Aug 2018 | cystic fibrosis | Bonnie Ramsey | Completed | No outcome recorded |
| Phase 3 | NCT01641822 Comparator | Dec 2012 → Jan 2015 | cystic fibrosis | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01315678 Comparator | Feb 2012 → Jun 2013 | Pseudomonas aeruginosa infectious disease | Insmed Incorporated | Completed | Met primary |
| Phase 3 | NCT01270347 Comparator | Jan 2011 → Oct 2012 | cystic fibrosis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01028027 Comparator | Oct 2009 → Feb 2010 | blepharitis, conjunctivitis, keratitis | Bausch & Lomb Incorporated | Completed | Met primary |
| Phase 3 | NCT01155999 Comparator | Dec 2008 → Feb 2011 | bacterial conjunctivitis | Laboratoires Thea | Completed | No outcome recorded |
| Phase 3 | NCT00757237 Comparator | Aug 2008 → May 2010 | cystic fibrosis | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00576251 Background | Oct 2007 → Feb 2008 | blepharoconjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00105469 Comparator | Jul 2004 → Oct 2005 | bacterial conjunctivitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00050401 Background | Jul 2002 → Sep 2004 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
| Phase 4 | NCT07072923 Comparator | Sep 2025 → Jul 2027 expected | osteomyelitis | University of Arizona | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06404541 Comparator | Jan → Apr 2024 | dry eye syndrome | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06093191 Comparator | Oct 2023 → Oct 2025 | Pseudomonas aeruginosa infectious disease, bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT04285320 Comparator | Mar 2021 → Apr 2023 | urinary tract infection | Atlantic Health System | Unknown | No outcome recorded |
| Phase 4 | NCT02677701 Comparator | Oct 2016 → Feb 2020 | cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02918409 Comparator | Aug 2016 → Sep 2020 | cystic fibrosis | National Jewish Health | Completed | No outcome recorded |
| Phase 4 | NCT02137161 Background | Nov 2013 → Oct 2014 | cataract, exfoliation syndrome | Azienda USL Reggio Emilia - IRCCS | Completed | No outcome recorded |
| Phase 4 | NCT01844778 Comparator | Aug 2013 → Oct 2015 | cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02873806 Background | Mar 2013 → Nov 2019 | open-angle glaucoma | Glaukos Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01677403 Comparator | Aug 2012 → Dec 2014 | bronchiectasis | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT01456780 Comparator | Aug 2011 → Mar 2013 | blepharitis | Massachusetts Eye and Ear Infirmary | Completed | No outcome recorded |
| Phase 4 | NCT01044719 Comparator | Jan → Oct 2010 | cystic fibrosis | Imperial College London | Unknown | No outcome recorded |
| Phase 4 | NCT00705159 Comparator | Jun 2008 → Mar 2010 | conjunctivitis | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 4 | NCT00447577 Background | Jan → Jun 2007 | keratoconjunctivitis | Bausch & Lomb Incorporated | Completed | Met primary |
| Phase 4 | NCT00781300 Comparator | Mar → Nov 2006 | ocular hypertension, open-angle glaucoma | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00532961 Comparator | Feb → Apr 2005 | — | Bausch & Lomb Incorporated | Completed | Met primary |
| Phase 4 | NCT01400750 Comparator | Aug 2001 → Aug 2010 | cystic fibrosis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT02528123 Background | Apr 2016 → Dec 2020 | myopia | London Vision Clinic | Completed | No outcome recorded |
| — | NCT02497365 Comparator | Sep 2015 → Jun 2019 | keratitis | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| — | NCT02489955 Comparator | Feb 2015 → Feb 2017 | cystic fibrosis | The Leeds Teaching Hospitals NHS Trust | Unknown | No outcome recorded |
| — | NCT02102152 Comparator | Apr 2014 → Apr 2016 | bronchiectasis | Rabin Medical Center | Unknown | No outcome recorded |
| — | NCT02526004 Background | Oct 2013 → Jun 2017 | cystic fibrosis | University College Cork | Completed | No outcome recorded |
| — | NCT01230593 Comparator | Nov 2010 → Jan 2016 | chalazion | McMaster University | Completed | No outcome recorded |
| — | NCT01103401 Comparator | Oct 2009 → Jan 2010 | cataract | Veroia General Hospital | Completed | No outcome recorded |
| — | NCT00992355 Comparator | Jan → Mar 2009 | cataract | Veroia General Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-04-01 | Alembic Pharmaceuticals Ltd. | Regulatory 22nd April, 2019, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tobramycin Ophthalmic Solution USP, 0.3%. |
| 2010-10-21 | Gilead Sciences | Results Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study gilead.com ↗
Patients receiving Cayston had an adjusted mean actual increase in FEV 1 percent predicted from baseline over six months of 2.05 percent compared to a 0.66 percent decrease for patients receiving TIS. |
| 2010-06-18 | Gilead Sciences | Results Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority gilead.com ↗
Patients receiving Cayston had a mean increase in FEV1 percent predicted from baseline to Day 28 of 8.35 percent compared to 0.55 percent for patients receiving TIS, which meets the statistical definition of superiority. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-13 | Xiromed LLC | Xiromed LLC Launches Tobramycin Vial for Injection, 1.2g xiromed.com ↗ |
| 2019-04-01 | Alembic Pharmaceuticals Ltd. | 22nd April, 2019, Vadodara, India alembicpharmaceuticals.com ↗ |
| 2010-10-21 | Gilead Sciences | Gilead's Cayston(R) Superior to Tobramycin Inhalation Solution in Six-Month Head-to-Head Cystic Fibrosis Study gilead.com ↗ |
| 2010-06-18 | Gilead Sciences | Gilead's Head-to-Head Study of Cayston(R) Versus Tobramycin Inhalation Solution in Cystic Fibrosis Patients Achieves Co-Primary Efficacy Endpoint of Non-Inferiority gilead.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 130 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tobramycin | “Gilead is developing a broad spectrum combination antibiotic (FTI) consisting of fosfomycin (an antibiotic with activity against gram-positive and gram-negative bacteria) and...” NCT00794586 ↗121“Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin,...” NCT07072923 ↗ “In the intervention arm, participants with airway microbiome positive for VAP pathogens will receive inhaled tobramycin, participants with airway S. aureus will receive inhaled...” NCT07463339 ↗ “This was a pilot, open-label clinical trial of tobramycin inhalation powder (TIP) delivered via Podhaler twice daily for 28days in adults and children with CF and chronic B....” PMID 28262569 ↗ Mar 2017 “A Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of SPRC-AB01, Tobramycin Solution for Nasal Inhalation, in...” NCT00447837 ↗ “Standard of Care + Local Vancomycin + Local Tobramycin: Participants in the treatment group will receive a dose of 1000mg of Vancomycin powder AND a dose of 1200mg of...” NCT04597008 ↗ “Protocol for Expanded Access to Cyclic Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Exchange Arthroplasty for Periprosthetic Joint...” NCT06383611 ↗ “The antibiotic bead pouch provides an antibiotic delivery mechanism. It is made by combining polymethyl methacrylate (PMMA) cement with generic forms of vancomycin and...” NCT05615844 ↗ “The SDD treatment comprises two oral liquids: an oral suspension containing amphotericin B and an oral solution containing both colistin sulfate and tobramycin.” PMID 41345690 ↗ Dec 2025 “A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx” NCT02389036 ↗ “Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.” NCT02334384 ↗ |
| Known as | Bethkis | “inhaled tobramycin nebulization solution 300 mg/4 ml (TNS4, Bramitob(®)/Bethkis(®)) was assessed over 56 weeks in CF patients” PMID 24464974 ↗ Jan 2014 |
| Known as | Gernebcin | “Tobramycin (Gernebcin®)” NCT00774072 ↗ |
| Known as | Nebcin | “Tobramycin, (Tobi, Tobrex, Nebcin)” NCT05849090 ↗ |
| Known as | SPRC-AB01 | “A Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of SPRC-AB01, Tobramycin Solution for Nasal Inhalation, in...” NCT00447837 ↗ |
| Known as | TIP | “This was a pilot, open-label clinical trial of tobramycin inhalation powder (TIP) delivered via Podhaler twice daily for 28days in adults and children with CF and chronic B....” PMID 28262569 ↗ Mar 20177“This is an integrated analysis of data from patients with cystic fibrosis (CF) aged 6-21 years who were treated with up to seven cycles of tobramycin powder for inhalation...” PMID 26709158 ↗ Dec 2015 “300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)” NCT02248922 ↗ “The ETOILES study (Clinicaltrials.gov identifier: NCT01519661) evaluated the safety of tobramycin inhalation powder (TIP) for 1 year.” PMID 27435882 ↗ Sep 2016 “Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate.” PMID 31433997 ↗ Aug 2019 “Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP.” NCT00918957 ↗ “Tobramycin Inhalation Powder (TIP) capsules for inhalation.” NCT00388505 ↗ “Tobramycin inhalation powder (TIP) 112mg/b.i.d” NCT01775137 ↗ |
| Known as | TIP(TM) | “This is an integrated analysis of data from patients with cystic fibrosis (CF) aged 6-21 years who were treated with up to seven cycles of tobramycin powder for inhalation...” PMID 26709158 ↗ Dec 2015 |
| Known as | TIS | “300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)” NCT02248922 ↗6“Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor” NCT01641822 ↗ “amikacin liposome inhalation suspension (ALIS, 590 mg QD) or tobramycin inhalation solution (TIS, 300 mg BID).” PMID 31451351 ↗ Aug 2019 “maintenance tobramycin inhalation solution (TIS) in bronchiectasis patients without cystic fibrosis” PMID 36531900 ↗ Dec 2022 “of tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily” PMID 19996339 ↗ Dec 2009 “nebulized tobramycin inhalation solution (TIS)” PMID 35863486 ↗ Jul 2022 “TIS (Tobramycin Inhalation Solution)” NCT01270347 ↗ |
| Known as | TNS4 | “inhaled tobramycin nebulization solution 300 mg/4 ml (TNS4, Bramitob(®)/Bethkis(®)) was assessed over 56 weeks in CF patients” PMID 24464974 ↗ Jan 2014 |
| Known as | TNS5 | “tobramycin 300 mg/5 ml (TNS5, TOBI(®))” PMID 24464974 ↗ Jan 2014 |
| Known as | TOBI | “The effectiveness, safety, and tolerability of Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available for use.” NCT01315678 ↗6“Tobramycin inhalation solution (TOBI) is an approved antibiotic, which is inhaled directly into the lungs” NCT00125346 ↗ “Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer” NCT00388505 ↗ “administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels.” NCT02212587 ↗ “tobramycin 300 mg/5 ml (TNS5, TOBI(®))” PMID 24464974 ↗ Jan 2014 “Tobramycin, (Tobi, Tobrex, Nebcin)” NCT05849090 ↗ “TOBI (tobramycin inhaled solution)” NCT01082367 ↗ |
| Known as | TOBI - tobramycin inhalation solution (TIS) | “TOBI® - tobramycin inhalation solution (TIS)” NCT01400750 ↗ |
| Known as | TOBI Podhaler | “300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)” NCT02248922 ↗ |
| Known as | TOBIr | “This study's primary goals are to test the safety and effectiveness of Tobramycin for Inhalation (TOBIr) in cystic fibrosis (CF) patients who are between 6 months and 6 years of age.” NCT00006280 ↗ |
| Known as | Tobramycin inhalation powder | “Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate.” PMID 31433997 ↗ Aug 20195“Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm” NCT02015663 ↗ “Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.” NCT00982930 ↗ “Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP.” NCT00918957 ↗ “Tobramycin Inhalation Powder (TIP) capsules for inhalation.” NCT00388505 ↗ “Drug: Tobramycin inhalation powder” NCT01069705 ↗ |
| Known as | Tobramycin inhalation powder (TIP) | “Tobramycin inhalation powder (TIP) 112mg/b.i.d” NCT01775137 ↗ |
| Known as | Tobramycin inhalation solution | “TOBI® is tobramycin inhalation solution” NCT01315678 ↗ |
| Known as | tobramycin powder for inhalation | “This is an integrated analysis of data from patients with cystic fibrosis (CF) aged 6-21 years who were treated with up to seven cycles of tobramycin powder for inhalation...” PMID 26709158 ↗ Dec 2015 |
| Known as | Tobramycin Solution for Inhalation | “Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer” NCT00388505 ↗ |
| Known as | Tobramycin Sulfate | “Protocol for Expanded Access to Cyclic Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Exchange Arthroplasty for Periprosthetic Joint...” NCT06383611 ↗ |
| Known as | Tobrex | “PURPOSE: To assess the within-treatment efficacy of hot compresses (HC), HC plus tobramycin (Tobrex) and HC plus tobramycin/dexamethasone (Tobradex) for chalazia treatment.” PMID 29338124 ↗ Jan 2018 |
| Route | Inhaled | “by inhalation” NCT00004829 ↗ |